In support of the robust antitumor response, the chitosan-SRA siRNA included in our combination immunotherapy regimen appears to help reprogram the immunologically ‘cold’ tumor microenvironment by recruiting more IFN-γ-producing CD8+ CTLs and IL-12+CD11c+ APCs, which are crucial for overcoming the immunosuppressive barriers in the tumor sites to achieve improved therapeutic outcomes. Here, ITGAX is linked to neoplasm.